A review of quality of life (QOL) concerning the salivary glands may focus on treatment of a salivary gland tumor, or xerostomia as a side effect of radiotherapy.
Quality of life studies about treatment of salivary gland tumors mainly focus on facial nerve function after surgery with or without postoperative radiotherapy. Prospective longitudinal studies on QOL issues concerning radiotherapy for salivary gland tumors cannot be found in the literature. As an indirect indicator of QOL, treatment resulting in improvement of locoregional control, and risk factors such as comorbidity and treatment-related side effects may be studied. For parotid gland tumors, the main side effects are facial nerve dysfunction, hearing loss, xerostomia, and temporal bone necrosis. Side effects of treatment of the submandibular gland and the minor salivary gland tumors strongly relate to the location of the tumor, and the possible need for elective or curative treatment of the neck nodes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anteunis LJC, Wanders SL, Hendriks JJT et al. (1994) A prospective longitudinal study on radiation-induced hearing loss. Am J Surg 168:408–411
Beal KP, Singh B, Kraus D et al. (2003) Radiation-induced salivary gland tumors: a report of 18 cases and a review of the literature. Cancer J 9:467–471
Beckhardt RN, Weber RS, Zane R et al. (1995) Minor salivary gland tumors of the palate: clinical and pathologic correlates of outcome. Laryngoscope 105:1155–1160
Bhattacharyya N (2004) Survival and prognosis for cancer of the submandibular gland. J Oral Maxillofac Surg 62:427–430
Bhattacharyya N, Fried MP (2005) Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol-Head Neck Med Surg 26:39–44
Bhide SA, Harrington KJ, Nutting CM (2006) Otological toxic-ity after postoperative radiotherapy for parotid tumours. Clinical Oncol 19:77–82
Borggreven PA, Verdonck@@@de Leeuw IM, Muller MJ et al. (2007) Quality of life and functional status in patients with cancer of the oral cavity and oropharynx: pre@@@treatment values of a prospective study. Eur Arch Otorhinolaryngol 264:651–657
Braam PM, Terhaard CH, Roesink JM et al. (2006) Intensity@@@modulated radiotherapy signifi cantly reduces xerostomia compared with conventional radiotherapy. Int J Radiat Oncol Biol Phys 66:975–980
Bragg CM, Conway J, Robinson MH (2002) The role of intensity@@@modulated radiotherapy in the treatment of parotid tumors. Int J Radiat Oncol Biol Phys 52:729–738
Bron L P, O'Brien CJ (1997) Facial nerve function after parotidectomy. Arch Otolaryngol Head Neck Surg 123(10):1091–1096
Brown PD, Eshleman JS, Foote RL et al. (2000) An analysis of facial nerve function in irradiated and unirradiated facial nerve grafts. Int J Radiat Oncol Biol Phys 48(3):737–743
Carinci F, Farina A, Pelucchi S et al. (2001) Parotid gland carcinoma: 1987–1997 UICC T classifi cations compared for prognostic accuracy at 5 years. Eur Arch Otorhinolaryngol 258:150–154
Carrillo JF, Vazquez R, Ramirez@@@Ortega M et al. (2007) Multivari ate prediction of the probability of recurrence in patients with carcinoma of the parotid gland. Cancer 109:2043–2051
Chen AM, Bucci MK, Quivey JM et al. (2006) Long@@@term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiation Oncology Biol Phys 67:1044–1050
Chen AM, Granchi PJ, Garcia J et al. (2007) Local@@@regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 67:982–987
Chen WC, Jackson A, Budnick AS et al. (2006) Sensorineural hearing loss in combined modality treatment of nasopha@@@ryngeal carcinoma. Cancer 106:820–829
Chen WQQQC, Liao CQQQT, Tsai HQQQC et al. (1999) RadiationQQQinduced hearing impairment in patients treated for malignant parotid tumor. Ann Rhinol Laryngol 108:1159–1164
Coulson S, O'Dwyer NJ, Adams RG et al. (2002) Expression of emotion and quality of life after facial nerve paralysis. Otol Neurotol 25:1014–1019
de Graeff A, Leeuw JRJ de, Ros, WJG et al. (2000) Pretreatment factors predicting quality of life after treatment for head and neck cancer. Head Neck 22:398–407
Derks W, de Leeuw JR, Hordijk GJ et al. (2005) Reasons for nonQQQstandard treatment in elderly patients with advanced head and neck cancer. Eur Arch Otorhinolaryngol 262(1):21–26
Dirix P, Nuyts S, Van den Bogaert W (2006) RadiationQQQinduced xerostomia in patients with head and neck cancer. Cancer 107:2525–2534
Douglas JG, Silbergeld DL, Laramore GE (2004) Gamma Knife stereotactic radiosurgical boost for patients treated primarily with neutron radiotherapy for salivary gland neoplasms. Stereotact Funct Neurosurg 82:84–89
Eisbruch A, Ten Haken RK, Kim HM et al. (1999) Dose, volume, and function relationships in parotid salivary glands following conformal and intensityQQQmodulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 45:577–587
Ferrier MB, Spuesens EB, Le Cessie S et al. (2005) Comorbidity as a major risk factor for mortality and complications in head and neck surgery. Arch Otolaryngol Head Neck Surg 131:27–32
Gallo O, Franchi A, Bianchi S et al. (1995) P53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer 75:2037–2044
Garden AS, elQQQNaggar AK, Morrison WH et al. (1997) Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 37:79–85
Garden AS, Weber RS, Ang KK et al. (1994) Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. Cancer 73:2563–2569
Garden AS, Weber RS, Morrison WH et al. (1995) The infl uQQQence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 32:619–626
Guida RA, Finn DG, Buchalter IH et al. (1990) Radiation injury to the temporal bone. Am J Otol 11:6–11
GuntinasQQQLichius O, Straesser A, Streppel M (2007) Quality of life after facial nerve repair. Laryngoscope 117:421–426
Honoré HB, Bentzen SM, Moller K et al (2002) SensoriQQQneural hearing loss after radiotherapy for nasopharyngeal carcinoma individualized risk estimation Radioth Oncol 65:9–16
Huber PE, Debus J, Latz D et al. (2001) Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol 59:161–167
Jaehne M, Roeser K, Jaekel T et al. (2005) Clinical and immunoQQQhistologic typing of salivary duct carcinoma. A report of 50 cases. Cancer 103:2526–2533
JereczekQQQFossa BA, Zarowski A, Milani F et al. (2003) RadiotherapyQQQinduced ear toxicity. Cancer Treat Rev 29:417–430
Jones AS, Beasley NJP, Houghton DJ et al. (1998) Tumours of the minor salivary glands. Clin Otolaryngol 23:27–33
Kam MK, Leung SF, Zee B et al. (2007) Prospective randomized study of intensityQQQmodulated radiotherapy on salivary gland function in earlyQQQstage nasopharyngeal carcinoma patients. J Clin Oncol 25:4873–4879
Kaplan MH, Feinstein AR (1974) The importance of classifying initial coQQQmorbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27(7–8):387–404
Kerrebijn JD, Freeman JL (1988) Facial nerve reconstruction: outcome and failures. J Otolaryngol 27(4):183–186
Kirkbride P, Liu FF, O'Sullivan B et al. (2001) Outcome of curative management of malignant tumors of the parotid gland. J Otolaryngol 30:271–279
Koul R, Dubey A, Butler J et al. (2007) Prognostic factors depic ting diseaseQQQspecifi c survival in parotidQQQgland tumors. Int J Radiat Oncol Biol Phys 68:714–718
Kwok HCK, Morton R, Chaplin JM et al. (2002) Quality of life after parotid and temporal bone surgery for cancer. Laryngoscope 112:820–833
LamersQQQKuijper E, Schwarz M, Rasch C et al. (2007) IntensityQQQmodulated vs. conventional radiotherapy of parotid gland tumors: potential impact on hearing loss. Med Dosim 32:237–245
Laramore GE, Krall JM, Griffi n TW et al. (1993) Neutron versus photon irradiation for unresectable salivary gland tumors: fi nal report of an RTOGQQQMRC randomized clinical trial. Int J Radiat Oncol Biol Phys 235–240
Lee TK, Rosen II, Gibbons JP et al. (2008) Helical tomotherapy for parotid gland tumors. Int J Radiat Oncol Biol Phys 70:883–891
Lim JJ, Kang S, Lee MR et al. (2003) Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, KiQQQ67 and prognosis. J Oral Pathol Med 32:552–561
Lopes MA, Santos GC, Kowalski LP (1998) Multivariate survival analysis of 128 cases of oral cavity minor salivary gland carcinomas. Head Neck 20:699–706
Low WK, Toh ST, Wee J et al. (2006) Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 24:1904–1909
Luukkaa H, Klemi P, Hirsimali P et al. (2008) Matrix metalloQQQproteinase (MMP)QQQ1, QQQ9, and QQQ13 as prognostic factors in salivary gland cancer. Acta OtoQQQLaryngologica 128:482–490
Magnano M, Gervasio CF, Cravero L et al. (1999) Treatment of malignant neoplasms of the parotid gland. Otolaryngol Head Neck Surg 121(5):627–632
Mendenhall WM, Morris CG, Amdur RJ et al. (2005) Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 103:2544–2550
MurdochQQQKinch CA, Kim HM, Vineberg KA et al. (2008) DoseQQQeffect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 72(2):373–82
Nishimura R, Baba Y, Murakimi R et al. (1997) MR evaluation of radiation otomastoiditis. Int J Radiat Oncol Biol Phys 39:155–160
North CA, Lee DJ, Piantadosi S et al. (1990) Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys 18:1319–1326
Nutting CM, Rowbottom CG, Cosgrove VP et al. (2001) Optimisation of radiotherapy for carcinoma of the parotid gland: a comparison of conventional, threeQQQdimensional conformal, and intensityQQQmodulated techniques. Radiother Oncol 60:163–172
Pan CC, Eisbruch A, Lee SJ et al. (2005) Prospective study of inner ear radiation dose and hearing loss in headQQQandQQQneck cancer patients. Int J Radiat Oncol Biol Phys 61:1393–1402
Parsons JT, Mendenhall WM, Stringer SP et al. (1996) Management of minor salivary gland carcinomas. Int J Radiat Oncol Biol Phys 35:443–454
Pathak I, Bryce G (2000) Temporal bone necrosis: diagnosis, classifi cation, and management. Otolaryngol Head Neck Surg 123:252–257
Piccirillo JF, Costas I (2004) The impact of comorbidity on outcomes. ORL 66:180–185
Pohar S, Gay H, Rosenbaum P et al. (2005) Malignant parotid tumors: presentation, clinical/pathologic prognostic factors, and treatment outcomes. Int J Radiat Oncol Biol Phys 61:112–118
Pommier P, Liebsch NJ, Deschler DG et al. (2006) Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg 132:1242–1249
Poulsen MG, Pratt GR, Kynaston B et al. (1992) Prognostic variables in malignant epithelial tumors of the parotid. Int J Radiat Oncol Biol Phys 23:327–330
Press MF, Pike MC, Hung G et al. (1994) Amplifi cation and overexpression of HERQQQ2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54:5675–5682
Raaijmakers E, Engelen AM (2002) Is sensorineural hearing loss a possible side effect of nasopharyngeal and parotid irradiation? A systematic review of the literature. Radioth Oncol 65:1–7
Reddy PG, Arden RL, Mathog RH (1999) Facial nerve rehabilitation after radical parotidectomy. Laryngoscope 109(6):894–899
Régis de Brito Santos I, Kowalski L P, Cavalcante de Araujo V et al. (2001) Multivariate analysis of risk factors for neck metastases in surgically treated parotid carcinoma. Arch Otolaryngol Head Neck Surg 127:46–60
Roesink J, Moerland M, Battermann J et al. (2001) Quantative doseQQQvolume response analysis of changes in parotid gland function after radiotherapy in the headQQQandQQQneck region. Int J Radiat Oncol Biol Phys 51:938–946
Rogers SN, Aziz A, Lowe D et al. (2006) Feasibility study of the retrospective use of the Adult Comorbidity Evaluation index (ACEQQQ27) in patients with cancer of the head and neck who had radiotherapy. Br J Oral Maxillofac Surg 44(4):283–8
Sanabria A, Carvalho AL, Vartanian JG et al. (2007) Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 14(4):1449–1457
Schramm VL, Imola MJ (2001) Management of nasophaQQQryngeal salivary gland malignancy. Laryngoscope 111:1533–1544
SchulzQQQErtner D, Nikoghosyan A, Jäkel et al. (2003) Feasibility and toxicity of combined photon and carbon ion radiotherapy for locally advanced adenoid cystic carcinomas. Int J Radiat Oncol Biol Phys 56:391–398
Schwarz S, Ettl T, Kleinsasser N et al. (2008) Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol 44:563–570
Spiro RH (1986) Salivary neoplasms: overview of a 35QQQyear experience with 2,807 patients. Head Neck Surg 8:177–184
Spiro RH, Armstrong J, Harrison L et al. (1989) Carcinoma of major salivary glands. Arch Otolaryngol Head Neck Surg 115:316–321
Spiro JD, Spiro RH (2003) Cancer of the parotid gland: role of the 7th nerve preservation. World J Surg 27(7):863–867
Storey MR, Garden AS, Morrison WH et al. (2001) Postoperative radiotherapy for malignant tumors of the submandibular gland. Int J Radiat Oncol Biol Phys 51:952–958
Sun EC, Curtis R, Melbye M et al. (1999) Salivary gland cancer in the United States. Cancer Epidemiol Biomark Prev 8:1095–1100
Swanson GM, Burns PB (1997) Cancers of the salivary gland: workplace risk among women and men. Ann Epidemiol 7:639–374
Terell JE, Ronis DL, Fowler KE et al. (2004) Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 130:401–408
Terhaard C, Lubsen H, Tan B et al. (2006) Facial nerve function in carcinoma of the parotid gland. Eur J Cancer 42(16): 2744–2750
Terhaard CHJ, Lubsen H, Rasch CRN et al. (2005) The role of radiotherapy in the treatment of malignant salivary gland tumours. Int J Radiat Oncol Biol Phys 61(1):103–111
Terhaard CHJ, Lubsen H, Van der Tweel et al. (2004) Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch Head and Neck Oncology Cooperative Group. Head Neck 26:681–693
Terhaard CHJ, van der Schroeff MP, Schie K van et al. (2008) Prognostic role of comorbidity in salivary gland carcinoma. Cancer 113:1572–1576
Therkildsen MH, Christensen M, Andersen LJ et al. (1998) Salivary gland carcinomas—prognostic factors. Acta Oncol 37:701–713
Vander Poorten V, Balm AJ, Hilgers FJ et al. (1999) The development of a prognostic score for patients with parotid carcinoma. Cancer 85(9):2057–2067
Vander Poorten VLM, Hart AAM, Van der Laan BFAM et al. (2003) Prognostic index for patients with parotid carcinoma. External validation using the nationwide 1985–1994 Dutch Head and Neck Oncology Cooperative Group Database. Cancer 97:1453–1463
Yaparpalvi R, Fontenla D P, Tyerech SK et al. (1998) Parotid gland tumors: a comparison of postoperative radiotherapy techniques using three dimensional (3D) dose distributions and doseQQQvolume histograms (DVHS). Int J Radiat Oncol Biol Phys 40:43–49
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Terhaard, C. (2009). Salivary Glands and Quality of Life. In: Harari, P.M., Connor, N.P., Grau, C. (eds) Functional Preservation and Quality of Life in Head and Neck Radiotherapy. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73232-7_7
Download citation
DOI: https://doi.org/10.1007/978-3-540-73232-7_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-73231-0
Online ISBN: 978-3-540-73232-7
eBook Packages: MedicineMedicine (R0)